Cargando…

Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial

Background A ‘Patient-Reported Outcome Measure, Inquiry into Side Effects’ (PROMISE) instrument was developed for patients to report common symptoms in clinical medication reviews. Objective To determine changes in patient-reported drug-associated symptoms collected by PROMISE before and after commu...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenmakers, Tim W. A., Wensing, Michel, De Smet, Peter A. G. M., Teichert, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840243/
https://www.ncbi.nlm.nih.gov/pubmed/29209863
http://dx.doi.org/10.1007/s11096-017-0575-7
_version_ 1783304538041614336
author Schoenmakers, Tim W. A.
Wensing, Michel
De Smet, Peter A. G. M.
Teichert, Martina
author_facet Schoenmakers, Tim W. A.
Wensing, Michel
De Smet, Peter A. G. M.
Teichert, Martina
author_sort Schoenmakers, Tim W. A.
collection PubMed
description Background A ‘Patient-Reported Outcome Measure, Inquiry into Side Effects’ (PROMISE) instrument was developed for patients to report common symptoms in clinical medication reviews. Objective To determine changes in patient-reported drug-associated symptoms collected by PROMISE before and after community pharmacist-led clinical medication reviews compared with usual care. Setting Community pharmacies in the Netherlands. Methods Patients were randomised into an intervention group (IG) and a control group (CG). PROMISE was used to collect symptoms experienced during the previous month, and any suspected drug-associated symptoms from both groups at baseline and at follow-up after 3 months. IG patients received a one-time clinical medication review, while CG patients received usual care. Main outcome measure Mean number of drug-associated symptoms at follow-up. Results Measurements were completed by 78 IG and 67 CG patients from 15 community pharmacies. Mean numbers of drug-associated symptoms per patient at follow-up were 4.0 in the IG and 5.0 in the CG, with an incident rate ratio between the groups of 0.90 (95% CI 0.62–1.33). Mean numbers of drug-associated symptoms per patient reported at follow-up and persisting since baseline were 2.1 in the IG and 2.6 in the CG, with an incident rate ratio of 0.85 (95% CI 0.43–1.42). The lowest percentages of persisting drug-associated symptoms detected in the IG were ‘palpitations’ and ‘stomach pain, dyspepsia’ while in the CG they were ‘stomach pain, dyspepsia’ and ‘trembling, shivering’. Conclusion PROMISE provided meaningful information on drug-associated symptoms in clinical medication reviews, however the number of drug-associated symptoms was not reduced by performing clinical medication reviews compared with usual care. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11096-017-0575-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5840243
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-58402432018-03-12 Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial Schoenmakers, Tim W. A. Wensing, Michel De Smet, Peter A. G. M. Teichert, Martina Int J Clin Pharm Research Article Background A ‘Patient-Reported Outcome Measure, Inquiry into Side Effects’ (PROMISE) instrument was developed for patients to report common symptoms in clinical medication reviews. Objective To determine changes in patient-reported drug-associated symptoms collected by PROMISE before and after community pharmacist-led clinical medication reviews compared with usual care. Setting Community pharmacies in the Netherlands. Methods Patients were randomised into an intervention group (IG) and a control group (CG). PROMISE was used to collect symptoms experienced during the previous month, and any suspected drug-associated symptoms from both groups at baseline and at follow-up after 3 months. IG patients received a one-time clinical medication review, while CG patients received usual care. Main outcome measure Mean number of drug-associated symptoms at follow-up. Results Measurements were completed by 78 IG and 67 CG patients from 15 community pharmacies. Mean numbers of drug-associated symptoms per patient at follow-up were 4.0 in the IG and 5.0 in the CG, with an incident rate ratio between the groups of 0.90 (95% CI 0.62–1.33). Mean numbers of drug-associated symptoms per patient reported at follow-up and persisting since baseline were 2.1 in the IG and 2.6 in the CG, with an incident rate ratio of 0.85 (95% CI 0.43–1.42). The lowest percentages of persisting drug-associated symptoms detected in the IG were ‘palpitations’ and ‘stomach pain, dyspepsia’ while in the CG they were ‘stomach pain, dyspepsia’ and ‘trembling, shivering’. Conclusion PROMISE provided meaningful information on drug-associated symptoms in clinical medication reviews, however the number of drug-associated symptoms was not reduced by performing clinical medication reviews compared with usual care. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11096-017-0575-7) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-12-05 2018 /pmc/articles/PMC5840243/ /pubmed/29209863 http://dx.doi.org/10.1007/s11096-017-0575-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Schoenmakers, Tim W. A.
Wensing, Michel
De Smet, Peter A. G. M.
Teichert, Martina
Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
title Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
title_full Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
title_fullStr Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
title_full_unstemmed Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
title_short Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
title_sort patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840243/
https://www.ncbi.nlm.nih.gov/pubmed/29209863
http://dx.doi.org/10.1007/s11096-017-0575-7
work_keys_str_mv AT schoenmakerstimwa patientreportedcommonsymptomsasanassessmentofinterventionsinmedicationreviewsarandomisedcontrolledtrial
AT wensingmichel patientreportedcommonsymptomsasanassessmentofinterventionsinmedicationreviewsarandomisedcontrolledtrial
AT desmetpeteragm patientreportedcommonsymptomsasanassessmentofinterventionsinmedicationreviewsarandomisedcontrolledtrial
AT teichertmartina patientreportedcommonsymptomsasanassessmentofinterventionsinmedicationreviewsarandomisedcontrolledtrial